Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (ABBV)
NYSE:ABBV
AbbVie (ABBV) Stock Price & Analysis
20,027 Followers
ABBV Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$125.85 - $181.20
Previous Close$162.64
Volume1.02M
Average Volume (3M)5.78M
Market Cap
$284.13B
Enterprise Value$334.58B
Total Cash (Recent Filing)$12.82B
Total Debt (Recent Filing)$59.38B
Price to Earnings (P/E)48.3
Beta0.37
Next Earnings
Jul 26, 2024EPS Estimate
$3.03Last Dividend Ex-Date
Apr 12, 2024Dividend Yield3.71%
Share Statistics
EPS (TTM)3.36
Shares Outstanding1,766,473,359
10 Day Avg. Volume5,586,682
30 Day Avg. Volume5,777,843
Standard Deviation0.07
R-Squared0.19
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)-3.64
Price to Sales (P/S)5.25
Price to Cash Flow (P/CF)14.80
P/FCF Ratio14.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.16
Enterprise Value/Gross Profit9.87
Enterprise Value/Ebitda20.89
Forecast
1Y Price Target
$186.17Price Target Upside13.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
AbbVie News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceAbbVie's solid financial performance is evidenced by a beat on top and bottom lines, along with an increase in FY24 EPS guidance, showcasing the company's confidence and strong commercial execution.
Pipeline DevelopmentAbbVie's pipeline updates, including promising treatments for Parkinson’s disease and schizophrenia, signal potential future growth and regulatory approvals, positioning the company for long-term success.
Product GrowthSkyrizi and Rinvoq continue to show robust momentum and strong growth projections, with Skyrizi poised for a successful launch in Ulcerative Colitis, further strengthening AbbVie's market position.
Bears Say
Competition And Market DynamicsInvestors appear concerned about Humira sales due to potential biosimilar competition and calls for greater biosimilar adoption.
Drug Safety And Regulatory ChallengesDermatologists will continue to prefer Dupixent for AD given its clean safety profile, which contrasts with Rinvoq’s safety risks and black box warning.
Financial Estimates And GuidancePrice target for the stock has been decreased to $187 from $195 due to updated Humira numbers and its impact on future earnings.
---
Ownership Overview
0.27% Insiders
21.66% Mutual Funds
22.70% Other Institutional Investors
55.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABBV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest stock price was $125.85 and its highest was $181.20 in the past 12 months.
What is AbbVie’s market cap?
Currently, no data Available
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jul 26, 2024 which is in 84 days.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Apr 26, 2024. The company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.26 by $0.05.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $1.55 which represents an annual dividend yield of 3.71%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is $3.03.
How many shares outstanding does AbbVie have?
AbbVie has 1,770,647,000 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.31 in its last earnings report, beating expectations of $2.26. Following the earnings report the stock price went down -4.585%.
Which hedge fund is a major shareholder of AbbVie?
Among the largest hedge funds holding AbbVie’s share is Diamond Hill Capital Management Inc. It holds AbbVie’s shares valued at 208M.
---
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$186.17 (13.87% Upside)
$186.17 (13.87% Upside)
Blogger Sentiment
Bullish
ABBV Sentiment 94%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 208.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $81.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
ABBV Earnings Call
Q1 2024
0:00 / 0:00
---
ABBV Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
ABBV Stock 12 Months Forecast
Average Price Target
$186.17
▲(13.87% Upside)
Technical Analysis
Best Analysts Covering ABBV
1 Year
1 Year Success Rate
20/23 ratings generated profit
1 Year Average Return
+16.58%
reiterated a buy rating 5 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 86.96% of your transactions generating a profit, with an average return of +16.58% per trade.
---